AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression

Endocr Relat Cancer. 2012 May 24;19(3):L25-9. doi: 10.1530/ERC-12-0020. Print 2012 Jun.

Authors

Leandro Kasuki, Leonardo Vieira Neto, Luiz Eduardo A Wildemberg, Leandro Machado Colli, Margaret de Castro, Christina M Takiya, Mônica R Gadelha

PMID: 22420004
DOI: 10.1530/ERC-12-0020

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acromegaly / drug therapy
Acromegaly / metabolism*
Adenoma / drug therapy
Adenoma / metabolism*
Adult
Antineoplastic Agents, Hormonal / therapeutic use
Female
Growth Hormone-Secreting Pituitary Adenoma / drug therapy
Growth Hormone-Secreting Pituitary Adenoma / metabolism*
Humans
Intracellular Signaling Peptides and Proteins / metabolism*
Male
Middle Aged
Octreotide / therapeutic use
Pituitary Neoplasms
Receptors, Somatostatin / metabolism*
Young Adult

Substances

Antineoplastic Agents, Hormonal
Intracellular Signaling Peptides and Proteins
Receptors, Somatostatin
SSTR2 protein, human
aryl hydrocarbon receptor-interacting protein
Octreotide